Alkem Laboratories Ltd., a major drug maker headquartered in Mumbai, has struck a licensing deal with the Indian clinical stage biotech firm Stempeutics Research Pvt Ltd for a stem cell therapy, Stempeucel, to which Alkem gains sole marketing rights. Stempeutics will manufacture and supply the product, which may become the first of its type in its intended use in India.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?